Arca
Skip to content
Tools
Tools

RAF serine/threonine protein kinase

Family in Homo sapiens that 2 drugs act on.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2
  • Genes: 3

Who is on it, and how far along

Every drug ChEMBL records acting on ARAF, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved1

  • Tovorafenib

Phase 30

    Phase 21

    • Belvarafenib

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      TovorafenibApprovedDay One BiopharmaceuticalsSmall moleculeInhibitorRAF serine/threonine protein kinase inhibitor9
      BelvarafenibPhase 2Hanmi PharmaceuticalSmall moleculeInhibitorRAF serine/threonine protein kinase inhibitor4

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 12 in all, from ClinicalTrials.gov.
      Belvarafenib for CNS Efficacy in Patients With BRAF-Altered Solid TumorsBelvarafenibPhase 2RecruitingSamsung Medical CenterJul 7, 2026
      A Clinical Study Evaluating the Safety, Tolerability, and Effect on HIV Reservoir of Ibalizumab Combined With Chidamide (a Histone Deacetylase Inhibitor) in People Living With HIVTovorafenibPhase 1Not yet recruitingFirst Affiliated Hospital of Zhejiang UniversityJun 9, 2026
      Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant MelanomaBelvarafenibPhase 2RecruitingHanmi Pharmaceutical Company LimitedMar 4, 2026
      A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain TumoursTovorafenibPhase 1Active, not recruitingIpsenMar 2, 2026
      Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)TovorafenibPhase 2Not yet recruitingNationwide Children's HospitalOct 3, 2025
      Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell LeukemiaTovorafenibPhase 1 / Phase 2RecruitingNational Cancer Institute (NCI)May 11, 2025
      Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade GliomasTovorafenibEarly phase 1RecruitingDaniel MorgensternApr 24, 2024
      A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell HistiocytosisTovorafenibPhase 2RecruitingNational Cancer Institute (NCI)Apr 25, 2023
      DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)TovorafenibPhase 3Active, not recruitingDay One Biopharmaceuticals, Inc.Oct 4, 2022
      Tovorafenib for Treatment of Craniopharyngioma in Children and Young AdultsTovorafenibPhase 2RecruitingSabine Mueller, MD, PhDJul 19, 2022
      A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.BelvarafenibPhase 1Active, not recruitingGenentech, Inc.Apr 8, 2021
      Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyBelvarafenibPhase 2Active, not recruitingHoffmann-La RocheOct 19, 2020

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3559685, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.